- Home
- RNAZ vs MDBH Comparison
RNAZ vs MDBH Comparison
Compare RNAZ & MDBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNAZ | MDBH |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 23.2M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | RNAZ | MDBH |
|---|---|---|
| Price | $1.77 | $1.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 26.9K | 4.1K |
| Earning Date | 08-14-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.52 | $1.75 |
| 52 Week High | $13.92 | $4.48 |
Technical Indicators
Market Signals| Indicator | RNAZ | MDBH |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 28.96 |
| Support Level | $1.55 | N/A |
| Resistance Level | $1.93 | $3.22 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 57.25 | 0.00 |
Price Performance
Historical ComparisonAbout RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
About MDBH MDB Capital Holdings LLC common
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.